switching between glp-1 agonists ๐Thereโs a growing trend youโre seeing for a reason: some patients are from medications to dual agonists., This isnโt about hype. Itโs about physiology., ๐ง GLP-1 like Semaglutide The current significance and prospects
Description
Mol Metab (2019) 30:72130
[5] Unknown Long-Term Consequences The most significant concern is that Ozempic overall is still a relatively new drug, particularly in the context of long-term, non-diabetic use for weight management
Some patients, termed super-responders, lose more weight than expected
A., Sattar N., et al
Nonexpression of GLP-1R is common in advanced pancreatic tumors with lymphatic metastasis and is associated with poor prognosis, suggesting that GLP-1R may inhibit tumorigenesis and metastasis of human pancreatic cancer cells both in vitro and in vivo
